EGFR/DHFR-IN-2

EGFR/DHFR-IN-2 (9b) is a dual h-DHFR/EGFRTK inhibitor, with IC50 values of 0.192 μM and 0.109 μM for h-DHFR and EGFR, respectively. EGFR/DHFR-IN-2 (9b) halts the cell cycle at the G1/S phase and induces apoptosis. EGFR/DHFR-IN-2 (9b) is a potential inhibitor of CYP2C9 and CYP3A4. EGFR/DHFR-IN-2 (9b) can be used in the cancer research[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Cytochrome P450; Dihydrofolate reductase (DHFR) ; EGFR

Related Pathways

Apoptosis; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

CCOC(C1=CC=C(C=C1)N2C(N)=C(C3(C(C#N)=C2O)C(C4=CC=CC=C4C3=O)=O)C#N)=O

Molecular Formula

C24H16N4O5

Molecular Weight

440.41

References & Citations

[1]Ahmed Ragab, Discovery and optimization of 2-pyridones as dual h-DHFR/EGFRTK inhibitors with immunomodulatory potential; design, synthesis, anti-proliferative activity, and apoptosis inducer, et al. Eur J Med Chem. 2025 May 10:294:117751.